Nimbus hopes to best Bristol’s Sotyktu

When Bristol Myers Squibb’s Sotyktu got approved in September with a relatively clean label, it was seen as a good thing for groups with next-generation Tyk2 inhibitors designed to be even more selective.

The hope is that greater selectively could lead to improved efficacy. Nimbus Therapeutics is the most advanced player here and will soon be putting this theory to the test, with phase 2 data on NDI-034858 in psoriasis due this quarter. But others are not far behind, and some analysts reckon that one rival, Ventyx, could have an even better compound.